Slide 1: Corporate Presentation
Corporate Presentation September 2025 +
Slide 2: Disclaimer
Disclaimer This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange, as amended (the “Exchange Act”), that are subject to risks and uncertainties. Forward-loo
Slide 3: CorMedix is a commercial pharmaceutical company focused on specialty injectables for acute care
CorMedix is a commercial pharmaceutical company focused on providing innovative specialty injectable products for acute care markets has transitioned into a diversified portfolio of specialty injectable therapies that is built upon a scalable commercial platform centered on acute care Attractive Fin
Slide 4: Synergistic Integration
The acquisition of Melinta represents a pivotal transformation for CorMedix and builds a platform positioned for future growth Rationale Strategic Builds dynamic platform that can accommodate additional products and expand as the combined company enters its next phase of business development Synergi
Slide 5: The Combined Portfolio Consists of a Diversified and Complementary Set of Assets
The Combined Portfolio Consists of a Diversified and Complementary Set of Assets Product Current Therapeutic Area Product Class Shared Call Points Taurolidine and heparin catheter CRBSI lock solution Candidemia and invasive candidiasis Echinocandin antifungal Hospitals & IDNs Serious infections incl
Slide 6: Combined revenue reached ~$160MM in 2024 with strong growth potential
Combined revenue reached ~$160MM in 2024 with strong growth potential fueled by DefenCath commercialization and multiple label expansion opportunities Pipeline and Growth Opportunities CorMedix Net Revenue1 $400 Therapeutic Ph III / Legacy Product Area Pre-Clinical Ph I Ph II Registra- Commercial Me
Slide 7: DefenCath is the first and only FDA-approved catheter lock solution
DefenCath is the first and only FDA-approved catheter lock solution with significant risk reduction in catheter related bloodstream infections (CRBSI) CRBSIs result in significant patient morbidity, mortality, and cost to healthcare systems ~2x more hospitalizations per year1 demonstrated significan
Slide 8: DefenCath is well positioned to capture value across outpatient and inpatient markets
DefenCath is well positioned to capture significant value across both outpatient and inpatient markets DefenCath Revenue DefenCath launched full scale for hemodialysis $50 in July 2024 $40 Strong commercial uptake with commercial Revenue (MM) agreements in place with 4 of the top 5 outpatient $30 DO
Slide 9: A TPN label expansion for DefenCath represents an opportunity of ~4.7MM infusions per year
A TPN label expansion for DefenCath represents an opportunity of ~4.7MM infusions per year across outpatient and inpatient settings, an addressable market of $500-750MM US Total Parenteral Nutrition Infection Risk in TPN Total Addressable Market 4 2024E 3.6 0.5 Ports or IVs Total Infusions (MM) 3 CV
Slide 10: Rezzayo disrupts the standard of care of daily echinocandins with once-weekly dosing
Rezzayo disrupts the standard of care of daily echinocandins with its once-weekly dosing schedule, highly simplifying management of candidemia and invasive candidiasis Next generation echinocandin with once-weekly dosing schedule – highly simplifies management of candidemia and invasive candidiasis
Slide 11: Expanded indication Phase 3 study (ReSPECT) for prophylaxis is underway
Expanded indication Phase 3 study (ReSPECT) for prophylaxis of invasive fungal infections is underway ReSPECT Ph III Global Multicenter Study • Study for the prevention of invasive fungal diseases in subjects undergoing allogeneic blood and marrow transplantation (BMT) • 13-week treatment of Rezafun
Slide 12: Rezzayo's label expansion into prophylaxis will unlock a >$2B TAM
Rezzayo’s label expansion into prophylaxis will unlock an opportunity of an additional ~130k addressable patients, representing a >$2B TAM Growth Opportunity Prophylaxis Addressable Patient Population 140 NHL, 23 Expands portfolio and reach into 120 hematology/oncology and transplant markets 100 SOT
Slide 13: Minocin, Vabomere, and the ORI franchise are highly differentiated anti-infectives
Minocin, Vabomere, and the ORI franchise (Kimrysa/Orbactiv) are highly differentiated anti-infectives with IP Coverage • Achieved ~$39MM revenue in 2024 • Achieved ~$20MM revenue in 2024 • Treats ABSSSI caused by gram- • Highly differentiated tetracycline with • Meropenem and vaborbactam positive pa
Slide 14: CorMedix has a proven leadership team with a long track record of commercial outperformance
CorMedix has a proven leadership team with a long track record of commercial outperformance JO INED CO RM EDIX PRIO R EXPERIEN CE • Chief Commercial Officer of Amneal Specialty Joe Todisco 2022 • Co-founder and Chief Executive of Gemini Laboratories Chief Executive Officer • Commercial Strategy and
Slide 15: Financial Highlights
Financial Highlights Key Statistics Balance Sheet as of 6/30/2025 Exchange NASDAQ Global Market Cash and short-term investments* $190.7 million** Common Stock 77.9 million shares as of August 2025 Convertible Debt*** $150 million Market cap*** ~$1.1 Billion Key Financials FY 2024 Net Revenue (CorMed
Slide 16: Anticipated Company Milestones
Anticipated Company Milestones 2H 2025 1H 2026 • Updates on Melinta integration • CorMedix year end earnings • CorMedix 3Q earnings • Updates on integration / synergies • DefenCath customer updates • TPN study updates • RWE study interim data • Rezzayo prophylaxis study updates • Presence and data p
Slide 17: CorMedix is well positioned to continue to create value as a diversified specialty pharma
CorMedix is well positioned to continue to create value as a diversified specialty pharma business with a compelling growth path Diversified Commercial Leader Life-Cycle Operating at Scale Management High-Growth, DefenCath Indication Platform for Full Suite Cash Flow Generating Expansion (TPN) of Ho
Slide 18: CorMedix is an ideal partner for the acute care market
CorMedix is an ideal partner for the acute care market due its dynamic commercial platform that can accommodate additional products Dynamic Commercial Platform Deep Commercial Acute Care Relationships Efficiency Specialization • Deep hospital relationships • 75+ customer-facing • Expertise in and pr
Slide 19: CorMedix Key Highlights
CorMedix Key Highlights Commercial specialty pharma business with portfolio of products, revenue scale, and a 1 dynamic commercial platform in acute care poised for organic and inorganic growth 2 Portfolio of hospital anti-infective products 3 DefenCath launch has been successful; ongoing roll out t